title: [What to expect from the neoadjuvant therapy of the oesophageal carcinoma?].
abstract: OBJECTIVE
  The aim of this study was to assess the neoadjuvant therapy of the oesophageal carcinoma firstly from the perspective of the immediate effect on the resection procedure itself and, secondly, from the perspective of the long-term results.
  
  
  METHODS
  Prior to the resection of the oesophagus, the patients were administered the neoadjuvant therapy. The patients were allocated to three groups with the following branches of the cytostatic treatment: CDDP+FU, TAX+FU a CDDP. A smaller group with a less advanced disorder was treated only surgically, with the oesophageal resection. Furthermore, the study aimed at assessing chemoresistance of the tumors according to the MTT test and at correcting the individual branches appropriately.
  
  
  RESULTS
  The total of 70 patients were operated from 2001 to V/2004. Out of this number, 15 oesophgeal resections without the neoadjuvant therapy were conducted. None of the patients exited, and fistules were the commonest complications.
  
  
  CONCLUSIONS
  No differences in postoperative complications were reported between the groups with or without the neodjuvant therapy. Therefore, this therapy has no positive effect on the resection results themselves. The MTT test proved to be of low significance in the neodjuvant therapy assessment. Chemoresistance can be assessed only retrospectively and, furthermore, the results are likely to be affected by a relatively high sensitivity to the neodjuvant therapy itself. The pCR rate reaches 20%. Long-term results had not been assessed due to a short follow-up period.
authors.affiliation: I. chirurgická klinika LF UP a FN v Olomouci.
authors.forename: V
authors.initials: V
authors.lastname: Král
authors.forename: C
authors.initials: C
authors.lastname: Neoral
authors.forename: R
authors.initials: R
authors.lastname: Aujeský
authors.forename: R
authors.initials: R
authors.lastname: Havlík
authors.forename: J
authors.initials: J
authors.lastname: Klein
authors.forename: M
authors.initials: M
authors.lastname: Hajdúch
authors.forename: P
authors.initials: P
authors.lastname: Benes
authors.forename: R
authors.initials: R
authors.lastname: Vrba
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D004938:Esophageal Neoplasms / Q000188:drug therapy* / Q000601:surgery; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D020360:Neoadjuvant Therapy; D017239:Paclitaxel / Q000008:administration & dosage; D011183:Postoperative Complications
chemical_list: D017239:Paclitaxel; D002945:Cisplatin; D005472:Fluorouracil